Gene Editing Stocks Are Setting Up 🌤️ The Morning Print

Good morning! 

Genomics stocks may be on the verge of a comeback, as they remain one of the few growth areas still building out a base.

Here's the setup.

In simple terms, genomics is the study of an organism's complete genetic blueprint.

These companies are developing technologies designed to modify, repair, and even rewrite DNA.

It's one of the most speculative corners of the healthcare sector, and the group has spent years largely out of favor.

This is the type of environment we're in, where gene editing stocks are back in focus.

The ARK Genomic Revolution ETF (ARKG) is now testing a key resistance level near $38.

A decisive breakout above that overhead supply would open the door to further upside, and a brand new uptrend.

Let's see if genomics can join the risk-on rally.